Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such
as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to …

Poor inhaler technique is frequent in asthma, but its long-term consequences have been
seldom assessed. Pharmacists are ideally positioned to teach inhaler technique. This …

Introduction Idiopathic pulmonary fibrosis (IPF) has an unpredictable course corresponding
to various profiles: stability, physiological disease progression and rapid decline. A minority …

Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung
cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this …

Idiopathic interstitial pneumonias (IIPs) comprise a heterogeneous group of rare lung
parenchyma disorders with high morbidity and mortality, which can occur at all ages. In …

Objective To describe the efficacy and safety of omalizumab, an anti‐IgE monoclonal
antibody, in patients with refractory and/or relapsing eosinophilic granulomatosis with …

Background Survivors of severe-to-critical coronavirus disease 2019 (COVID-19) may have
functional impairment, radiological sequelae and persistent symptoms requiring prolonged …

Nivolumab is an anti-PD1 antibody, given in second-line or later treatment in advanced non-
small cell lung cancer (NSCLC). The objective of this study was to describe the predictive …

BACKGROUND: Air trapping reflects small airway obstruction in asthma and can be
assessed quantitatively by high-resolution computed tomography (HRCT) …

Background Recent data suggested a role of gut microbiota and antibiotic use on immune
checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic …